(Press-News.org)
Sophia Antipolis, 27 March 2023: Patients with atrial fibrillation (AF) benefit from early rhythm control therapy. It reduces cardiovascular deaths, strokes, and other adverse outcomes by 20% compared to usual care. The beneficial effects of early rhythm control were shown by the pan-European EAST – AFNET 4 trial and confirmed by other large health studies. However, what is the price of the new treatment strategy? A cost-effectiveness analysis revealed: the health benefits of early rhythm control come at reasonable additional costs. The analysis was published today in EP Europace, a journal of the European Society of Cardiology (ESC) [1].
Atrial fibrillation is a rising epidemic. The number of AF patients in the European Union is projected to increase to approximately 18 million by 2060. Affected persons are at higher risk for stroke and other adverse events associated with high costs for treatment and long-term care. This leads to an increasing economic burden.
The EAST – AFNET 4 (Early Treatment of Atrial Fibrillation for Stroke Prevention) trial investigated whether rhythm control therapy – with antiarrhythmic drugs or atrial fibrillation ablation – delivered within one year after AF diagnosis improves outcomes. The main study result, published in 2020 [2], demonstrated that early rhythm control therapy improves outcomes in patients with AF and comorbidities: early rhythm control with antiarrhythmic drugs and/or AF ablation reduced the primary outcome, a composite of cardiovascular death, stroke, and hospitalisation for worsening heart failure or acute coronary syndrome, in 2,789 patients with early AF and cardiovascular risk factors compared to usual care over a 5-year follow-up.
“The health benefit of early rhythm control is evident. However, the cost-effectiveness of the new treatment strategy has not been evaluated so far. One concern after the publication of the EAST – AFNET 4 main study was whether the additional treatment would add an acceptable or undue financial burden to healthcare systems. In the current analysis, we examined for the first time the cost-effectiveness of early rhythm control compared to usual care,” explained Sophie Gottschalk, Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, Hamburg Center for Health Economics, Hamburg, Germany.
The cost-effectiveness analysis was based on data from the German subsample of the EAST – AFNET 4 trial comprising 1,664 patients (see graphical abstract). Early rhythm control in 832 patients was compared to usual care in 832 patients over a 6-year time horizon and from a German healthcare payer perspective. Cost categories considered in the analysis were hospitalisation and medication costs. The time to the occurrence of a primary outcome and the time survived in the observation period were used as effect measures.
Incremental cost-effectiveness ratios (ICERs) were calculated for each effect measure. The ICER value describes the additional costs needed for an additional year free of primary outcome events or an additional life year, respectively. The analysis showed: early rhythm control was associated with higher costs to the amount of €1,924, resulting in ICERs of €10,638 per additional year without a primary outcome, and €22,536 per life year gained. As shown in the uncertainty analysis, high probabilities of cost-effectiveness could be reached if the healthcare payer was willing to pay ≥€55,000 for an additional year without a primary outcome or for a life year gained (probabilities ≥95% or ≥80%, respectively).
The principal investigator of EAST – AFNET 4, Prof. Paulus Kirchhof, Department of Cardiology, University Heart and Vascular Center Hamburg-Eppendorf, Hamburg, Germany, concluded: “The health benefits of early rhythm control come at reasonable additional costs as indicated by our analysis of the EAST – AFNET 4 study data for Germany. The added cost is comparable to the cost of other therapies reducing outcomes, and within typical ranges of acceptable payments in Germany. Future studies examining the cost-effectiveness of early rhythm control in other countries, in subgroups with higher benefit from rhythm control therapy, or the cost-effectiveness of different modes of early rhythm control are warranted.”
Since the publication of the main study result in 2020, different subgroup analyses of the EAST – AFNET 4 study data have been performed. One described the different, variable treatment patterns of antiarrhythmic drugs and AF ablation used in the trial, applied within guideline recommendations [3]. Other subgroup analyses demonstrated the prognostic benefit of early rhythm control in patients with AF and heart failure [4], in patients with asymptomatic AF [5], in patients with different AF patterns [6], in patients with high comorbidity burden [7] and in patients with prior stroke [8]. A mediator analysis identified sinus rhythm as a key factor for the effectiveness of early rhythm control [9].
The EAST – AFNET 4 trial has partners across Europe including the European Heart Rhythm Association (EHRA) of the ESC.
Graphical abstract
Notes: ERC, early rhythm control therapy; ICER, incremental cost-effectiveness ratio; primary outcome event = cardiovascular death, stroke, or hospitalisation for stroke or acute coronary syndrome.
END
A new study examining the gene expression of gut microbes suggests that the heart-healthy benefits of walnuts may be linked to beneficial changes in the mix of microbes found in our gut. The findings could help identify other foods or supplements with similar nutritional benefits.
Researchers led by Kristina S. Petersen from Texas Tech University in Lubbock found that introducing walnuts into a person’s diet may alter the gut’s mix of microbes — known as the microbiome — in a way that increases the body’s production of the ...
Results from the NRG Oncology Phase II NRG-GOG-0279 clinical study indicate that women with locally advanced squamous cell carcinoma of the vulva who received gemcitabine concurrently with cisplatin and intensity-modulated radiation therapy (IMRT) exhibited increased rate of pathologic complete responses (pCR). This is also the first clinical trial to standardize IMRT. These findings were presented during the Plenary Session at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
“Women with locally ...
Locally advanced cervical cancer remains an area of high therapeutic need, with recent trials failing to demonstrate evidence of benefit from adjuvant chemotherapy or immune checkpoint blockade administered concurrent with chemoradiation. Results from the NRG-GY017 randomized trial comparing the anti-PD-L1 inhibitor atezolizumab before and concurrent with chemoradiation (CRT) indicated favorable outcomes for 2-year disease-free survival (DFS) and demonstrated evidence of improved immunogenicity with neoadjuvant atezolizumab in patients with locally advanced cervical cancer. These findings were presented during the Plenary Session at the Society of Gynecologic ...
Marseille, France – 26 March 2023: More than 40% of women report anxiety four months after a cardiac arrest compared with 23% of men, according to research presented today at ESC Acute CardioVascular Care 2023, a scientific congress of the European Society of Cardiology (ESC).1
“Cardiac arrest occurs with little or no warning and it’s common to feel anxious and low afterwards,” said study author Dr. Jesper Kjaergaard of Rigshospitalet - Copenhagen University Hospital, Denmark. “After the initial shock and confusion, patients and their families have an abrupt change in their way of life, with medical investigations ...
A statewide effort to treat the pain of surgery patients without increasing their risk of long-term dependence on opioids has paid off in Michigan, a study shows.
In less than two years, the effort led to a 56% reduction in the amount of opioids patients received after having six different common operations, and a 26% drop in the chance that they would still be filling opioid prescriptions months after their surgical pain should have eased.
Both of those drops beat national trends for similar patients, according to the new study published ...
Business alliances are valuable because they help companies supplement critical skills, enter new markets, and gain competitive advantages.
In the pharmaceutical industry, strategic alliances are common because they help companies reduce risks and share the large R&D costs of bringing new drugs to market — like the partnership of Pfizer and BioNTech on vaccines. Such partnerships can take years to develop and are critical to a pharma company’s success.
But when biopharmaceutical companies merge, preserving their preexisting alliances isn’t always a priority, according to a new Texas McCombs study.
“High-performing alliances ...
CHICAGO—March 24, 2023—Illinois Institute of Technology Assistant Professor Ren Wang has been honored with the National Science Foundation’s Computer and Information Science and Engineering Research Initiation Initiative (CRII) award. The two-year grant will support Wang’s groundbreaking research project, which aims to enhance the robustness of machine learning models by infusing key principles of the immune system into neural networks.
Wang’s innovative project, titled “Immune-Inspired Learning Foundations of Neural Network General Robustness,” not only advances the theory and ...
**Note: the release below is a special early release from the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2023, Copenhagen, 15-18 April). Please credit the congress if you use this story**
Embargo: 2301H UK time Friday 24 March
Most patients admitted to hospital with acute viral respiratory infections are given antibiotics. Now new research to be presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark (15-18 April), suggests that prescribing antibiotic therapy to adults hospitalised with common viral respiratory infections such as influenza is unlikely to ...
A major new study confirms the trend to fewer suicides in Europe. The findings show that suicide rates are down in 15 countries (including Germany and Italy), and stable elsewhere (including France, Spain and UK). Only Türkiye shows a significant increase. This work is presented for the first time at the European Congress of Psychiatry in Paris.
Suicide is one of the major causes of premature death, globally around 700,000 suicides are reported each year. European suicide rates have been generally ...
EAST LANSING, Mich. – Phosphorus is a natural mineral that is essential for plant growth and development, and Earth’s agricultural-grade phosphorus reserves are expected to be depleted in 50 to 100 years. A new discovery by researchers at Michigan State University and the Carnegie Institution for Science is changing their understanding of iron toxicity in plants caused by low phosphorus levels.
“Once the world’s supply is used up, we can’t make more phosphorus,” said Hatem Rouached, an assistant professor in MSU’s ...
